Despite these limitations, to the best of our knowledge, this is the first study to show the dynamics of sPD-L1 levels in unresectable pancreatic cancer patients treated with homogenous FOLFIRINOX chemotherapy. This evidence concerns the gene SPDL1 and pancreatic neoplasm.